Man Group’s Disc Medicine IRON Stock Holding History

Man Group’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	14,925 +4,919	+49%	+$338K	﹤0.01%	1827
2026 Q1	$640K	Buy	+10,006	New	+$694K	﹤0.01%	1996

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Man Group's IRON Position: Q2 2026 in Review

Man Group increased its Disc Medicine (IRON) stake by 49% in Q2 2026, buying an estimated $338K and bringing the position to 14,925 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Man Group first reported a position in IRON in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

Man Group held 14,925 shares of Disc Medicine worth $1.09M as of Q2 2026.
Man Group bought 4,919 Disc Medicine shares in Q2 2026, an estimated $338K.
Disc Medicine made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1827 holding.
Man Group first reported a position in Disc Medicine in Q1 2026 and has held it in 2 quarters since.
216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.